Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27517425 | 0.87 | NPC1 (0.55) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL13996081 | 0.83 | ALDH1A1 (0.51) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Carbamic Acid SCHEMBL28732757 | 0.81 | KMT2A (0.50) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL3165362 | 0.80 | MEN1 (0.57) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL18760499 | 0.80 | MEN1 (0.57) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL8134255 | 0.80 | MEN1 (0.70) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL8143320 | 0.79 | LMNA (0.61) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL11013258 | 0.79 | ADORA2A (0.59) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2580556 | 0.78 | LMNA (0.58) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL16815412 | 0.78 | MEN1 (0.45) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010033466-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE | PHENOMIX CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-2118091-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | Tibotec Pharmaceuticals (IE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | MEN1 4587/4885KMT2A 4374/4885MAPT 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.